Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0071

Investigator meeting · Dr. Oscar Yamamoto

24 May 2026 · In person · Dr. Oscar Yamamoto, Memorial Sloan Kettering · MSL James Whitfield · Vantrexa

ReviewedManualENG-0071—

Capture insight from this engagement

Location: Memorial Sloan Kettering
Therapeutic area: Oncology
Country: United States
Stakeholder tier: Tier 3
Strategic objective: Not linked
Initiative: Not linked
MSL: JWJames WhitfieldSenior MSL, Oncology (US East)
Product: Vantrexa (vantrelimab)

Topics discussed

Chemotherapy-free first line

Scientific content used

PD-L1 testing pathway infographic
VOYAGE-1 pivotal data summary

Questions raised

No questions recorded.

Notes

Investigator meeting with oncology pharmacist at Memorial Sloan Kettering. Discussed chemotherapy-free first line.

Insights captured (1)

Capture insight

INS-0023High
Chemotherapy-free first line
Chemotherapy-free first line: request for data reported by oncology pharmacist (US).
Outcome recorded

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Connect with Clinical Development

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 4
Strategic relevance: 5
Depth of exchange: 5
Actionability: 1

Data lineage

Source system: Manual
Sync: Entered manually in Hub
System of record: Hub
Record id: ENG-0071

Audit history (0)

All create, update and approval events for this record

No audit events in sample data